

1 Shared genetic basis informs the roles of polyunsaturated 2 fatty acids in brain disorders

3 Huifang Xu^{1*}, Yitang Sun^{1*}, Michael Francis², Claire F. Cheng¹, Nitya T.R. Modulla¹, J. Thomas
4 Brenna^{3,4,5}, Charleston W. K. Chiang^{6,7}, Kaixiong Ye^{1,2#}

5 ¹Department of Genetics, University of Georgia, Athens, Georgia;

6 ²Institute of Bioinformatics, University of Georgia, Athens, Georgia;

7 ³Dell Pediatric Research Institute and Department of Pediatrics, The University of Texas at
8 Austin, Texas;

9 ⁴Dell Pediatric Research Institute and Department of Chemistry, The University of Texas at
10 Austin, Texas;

11 ⁵Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at
12 Austin, Texas;

13 ⁶Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck
14 School of Medicine, University of Southern California, Los Angeles, California;

15 ⁷Department of Quantitative and Computational Biology, University of Southern California, Los
16 Angeles, California;

17

18 *Co-first authors

19 #Corresponding author: kaixiong.ye@uga.edu

20 **Abstract**

21 The neural tissue is rich in polyunsaturated fatty acids (PUFAs), components that are
22 indispensable for the proper functioning of neurons, such as neurotransmission. PUFA nutritional
23 deficiency and imbalance have been linked to a variety of chronic brain disorders, including
24 major depressive disorder (MDD), anxiety, and anorexia. However, the effects of PUFAs on
25 brain disorders remain inconclusive, and the extent of their shared genetic determinants is largely
26 unknown. Here, we used genome-wide association summary statistics to systematically examine
27 the shared genetic basis between six phenotypes of circulating PUFAs (N = 114,999) and 20
28 brain disorders (N = 9,725-762,917), infer their potential causal relationships, identify
29 colocalized regions, and pinpoint shared genetic variants. Genetic correlation and polygenic
30 overlap analyses revealed a widespread shared genetic basis for 77 trait pairs between six PUFA
31 phenotypes and 16 brain disorders. Two-sample Mendelian randomization analysis indicated
32 potential causal relationships for 16 pairs of PUFAs and brain disorders, including alcohol
33 consumption, bipolar disorder (BIP), and MDD. Colocalization analysis identified 40 shared loci
34 (13 unique) among six PUFAs and ten brain disorders. Twenty-two unique variants were
35 statistically inferred as candidate shared causal variants, including rs1260326 (*GCKR*), rs174564
36 (*FADS2*) and rs4818766 (*ADARBI*). These findings reveal a widespread shared genetic basis
37 between PUFAs and brain disorders, pinpoint specific shared variants, and provide support for
38 the potential effects of PUFAs on certain brain disorders, especially MDD, BIP, and alcohol
39 consumption.

40 **Introduction**

41 Disorders of the brain contribute significantly to the global disease burden [1, 2]. For
42 example, in 2019, more than 970 million individuals suffered from 12 mental disorders, ranging
43 from 13.6 million for eating disorders to 301.4 million for anxiety disorders [2]. These disorders
44 encompass a wide range of psychiatric and neurological symptoms, including cognitive
45 impairment, emotional dysregulation, and behavioral disturbances, all of which profoundly
46 disrupt the life of the patients, and can in severe cases lead to suicide [3]. Effective prevention
47 and treatment of brain disorders are of utmost importance in improving clinical symptoms and
48 overall quality of life. One promising and emerging therapeutic approach is nutritional medicine
49 [4], which seeks to prevent the onset of brain disorders or alleviate their clinical manifestations
50 by implementing specific nutritional interventions [4, 5].

51 Brain structural lipids are rich in long-chain omega-3 and omega-6 polyunsaturated fatty
52 acids (PUFAs) [6]. Dietary deficiency of omega-3 PUFAs leads to global deficits in neural
53 function in experimental animals [7]. In humans, PUFAs and particularly omega-3s, have been
54 suggested to have protective and therapeutic effects on brain disorders because they regulate
55 physiological processes such as neuroinflammation, neurotransmission, and neuron survival [4, 6,
56 8]. Omega-3 supplementation has shown promising results in reducing clinical symptoms
57 associated with a range of brain conditions, including MDD [9, 10], anxiety disorders [11],
58 schizophrenia [12, 13], attention-deficit/hyperactivity disorder (ADHD) [14], autism spectrum
59 disorder [15] and Alzheimer's disease (ALZ) [16]. However, several randomized controlled trials
60 reported small or no effects of PUFAs on schizophrenia [5], depression [17], ALZ [18] and
61 psychosis [19, 20]. Consequently, the overall impact of PUFAs on human brain disorders
62 remains inconclusive, necessitating further investigation to establish their therapeutic potential.

63 While observational associations are commonly confounded by unknown or unmeasured
64 factors [21], exploring the shared genetic basis between PUFAs and brain disorders offers
65 valuable insights into their shared biological pathways and potential causal relationships [22].
66 Previous studies have leveraged genetic information to investigate the connections between
67 PUFAs and brain disorders (**Supplementary Table S1**), such as the application of Mendelian
68 randomization (MR) to statistically infer causal relationships. For instance, a recent MR study
69 suggested that decreased docosahexaenoic acid (DHA) and increased omega-6 to omega-3 ratio
70 have causal links with MDD, and it further identified the fatty acid desaturase (*FADS*) gene
71 cluster as a common genetic signal [23]. In an experimental study, mice with *Fads1/2* genes
72 knockout were used to simulate the effect of BIP risk allele on *Fads1/2* activity, revealing
73 significant changes in lipid profile and behavioral alterations [24]. However, current genetic
74 studies primarily concentrate on specific brain disorders (e.g., MDD [23, 25], SCZ [26, 27], and
75 BIP [24, 28]) or a limited number of genes, such as *FADS* [23, 24, 26, 28] and *ELOVL2/5* [26].
76 Therefore, it is necessary to explore the broader genomic landscape to ascertain additional
77 genetic determinants that underlie the connection between PUFAs and brain disorders.

78 Our study aims to systematically explore the shared genetic basis between the levels of
79 circulating PUFAs (cPUFAs) and brain disorders, infer their potential causal relationships,
80 identify shared genomic regions, and pinpoint specific shared genetic variants. We performed
81 four major analyses using genome-wide association study (GWAS) summary statistics for six
82 cPUFA phenotypes (N = 114,999) and 20 brain disorders (N = 9,725-762,917). First, we
83 estimated genetic correlation, and second, quantified the number of shared genetic variants,
84 between cPUFA phenotypes and brain disorders. Third, we performed MR analysis to
85 statistically infer causal associations between cPUFAs and brain disorders. Lastly, we conducted

86 colocalization analysis and statistical fine-mapping to identify colocalized regions and pinpoint
87 putative shared causal variants. Collectively, our study characterizes the shared genetic basis and
88 informs the relationships between cPUFAs and brain disorders.

89 **Methods**

90 **GWAS summary statistics and preprocessing**

91 Six cPUFA phenotypes and 20 brain disorders were included in the study
92 (**Supplementary Figure S1; Supplementary Table S2**). The six cPUFA traits were the relative
93 percentages of total PUFAs, omega-3, omega-6, DHA, and linoleic acid (LA) in total fatty acids,
94 and the omega-6 to omega-3 ratio. They are abbreviated as PUFA%, omega-3%, omega-6%,
95 DHA%, LA%, and omega-6:omega-3, respectively. The 20 brain disorders included
96 schizophrenia (SCZ) [29], MDD [30], BIP [31], obsessive-compulsive disorder (OCD) [32],
97 anxiety disorders and factors (ANX) [33], post-traumatic stress disorder (PTSD) [34], anorexia
98 nervosa (AN) [35], autism spectrum disorder (ASD) [36], Tourette syndrome (TS) [37], attention
99 deficit-hyperactivity disorder (ADHD) [38], mood disorders (MOOD), insomnia (INS) [39],
100 neuroticism (NE) [40], ALZ [41], opioid dependence (OD) [42], cannabis use disorder (CUD)
101 [43], alcohol dependence (AD) [44], alcohol use disorder identification test total score
102 (AUDIT_T), AUDIT focusing on alcohol consumption (AUDIT_C) and AUDIT focusing on the
103 problematic consequences of drinking (AUDIT_P) [45].

104 Publicly available GWAS summary statistics of all cPUFAs and brain disorders were
105 downloaded from IEU Open GWAS [46] and Psychiatric Genomic Consortium (PGC) [47].
106 GWAS summary statistics for insomnia [39] were downloaded from the Center for
107 Nutrigenomics and Cognitive Research (CNCR, https://ctg.cncr.nl/software/summary_statistics).
108 Multiple GWAS for each of seven brain disorders (i.e., SCZ, BIP, MDD, INS, ALZ, AN, ASD)
109 were included for replication analysis (**Supplementary Table S2**). A total of 34 GWAS for brain
110 disorders and 11 GWAS for cPUFAs were examined. Four GWAS were removed from our study
111 for reasons including 1) no clear information indicating effect allele (n=2) [48, 49]; 2) incorrect

112 data format (n=1) [50]; 3) the number of cases is less than 1000 (n=1) [51]. We focused on
113 European ancestry to align ancestry across studies. Phenotypes associated with alcohol intake
114 (AD, AUDIT_T, AUDIT_C, AUDIT_P) had pairwise genetic correlations less than 1 [45], and
115 therefore were analyzed separately.

116 All GWAS summary statistics were harmonized to ensure data quality and consistency.
117 Summary statistics of three GWAS from hg18 reference genome build were converted into
118 hg19/GRCh37 genome build by Lifter [52]. MungeSumstats (v1.3.17) [53] was used to
119 harmonize all GWAS summary statistics including: 1) uniformity in strand designation; 2)
120 uniformity in SNP ID; 3) same effect allele; 4) effect size and standard error, or Z score are
121 included; 5) hg19/GRCh37 reference genome build is used; 6) uniformity in the p-value format;
122 7) removal of InDels; 8) removal of SNPs with low genotype imputation quality (INFO < 0.3).
123 After harmonization, a total of 10,568,861 SNPs for six cPUFAs and 1,147,602 to 14,124,455
124 SNPs for 20 brain disorders were included in the downstream analysis (**Supplementary Table**
125 **S2**). For each trait, we mainly focused on the GWAS with the largest sample size, and the rest
126 were presented in supplementary results.

127 **Estimation of SNP-based heritability (h^2_{SNP}) and pairwise genetic correlation (r_g)**

128 Linkage Disequilibrium Score regression (LDSC, v1.0.1) [54] was applied to estimate
129 SNP-based heritability (h^2_{SNP}) for each phenotype using GWAS summary statistics. For case-
130 control traits, h^2_{SNP} was converted to the liability-scale by considering the disease prevalence and
131 sample proportion (**Supplementary Table S2**). For quantitative traits, the observed-scale
132 heritability was estimated.

133 Cross-trait LDSC [55] was used to compute pairwise genetic correlations (r_g) using
134 GWAS summary statistics between six cPUFAs and 20 brain disorders. Pre-computed reference

135 panel LD score of European samples in the 1000 Genomes Project (1KGP) phase 3 [56] was
136 downloaded from https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2.
137 SNP-based heritability and pairwise genetic correlation analyses were run using Hapmap3 SNPs
138 with imputation INFO > 0.9 and minor allele frequency (MAF) > 1%. SNPs in the major
139 histocompatibility complex (MHC) region were excluded. P-value cutoffs of 0.05, 0.001, and
140 0.05 divided by the number of tests (i.e., the Bonferroni-corrected threshold) were used to
141 represent different levels of statistical significance. Genetic correlation coefficients and p-values
142 were visualized using the R corrplot (v0.92) package [57].

143 **Estimation of polygenicity**

144 To estimate the number of common variants that are associated with cPUFAs or brain
145 disorders, a univariate Gaussian mixture model in MiXeR [58] was applied to the GWAS
146 summary statistics. We restricted the univariate analysis to 19 brain disorder GWAS
147 (corresponding to 15 unique phenotypes) with $N > 46,000$ to ensure statistical power. Five
148 GWAS for ANX, OCD, TS, OD, AD had small sample sizes and were not included in the
149 analysis. Pre-computed EUR reference panel LD score was used as in the LDSC analysis. To
150 ensure compatibility with MiXeR, we utilized the `munge_sumstats.py` script provided by MiXeR
151 to further process GWAS summary statistics. This step was necessary to meet the specific
152 requirements of MiXeR, particularly addressing the sample imbalance in case-control
153 phenotypes by utilizing the effective sample size ($N_{eff} = \frac{4}{\frac{1}{N_{case}} + \frac{1}{N_{control}}}$). Additionally, we
154 obtained information on allelic LD r^2 correlations and allele frequency in the 1KGP European
155 samples from the MiXeR GitHub repository. MiXeR provides a reference set of about 11 million
156 SNPs, which is used to estimate the number of trait-associated variants that explain 90% of h^2_{SNP} .

157 **Quantification of polygenic overlap between cPUFAs and brain disorders**

158 The MiXeR bivariate causal mixture model [59] was applied to quantify the number of
159 variants that have nonzero effects on both traits (nc_{12}). We performed cross-trait analyses to
160 estimate polygenic overlap between cPUFAs and brain disorders, including six GWAS for six
161 cPUFAs and 19 GWAS for 15 brain disorders. The bivariate analysis provides the proportion
162 (π_{12}), number (nc_{12}), and correlation of effect size within the shared polygenic components (ρ_{12}).
163 We calculated Z -statistics using the formula $Z = \beta/SE$ and visualized the effect sizes of all
164 SNPs in pairs of GWAS summary statistics using the R hexbin (v1.28.2) package. We used R
165 ComplexHeatmap (v2.14.0) [60] package to visualize the number of shared variants between
166 cPUFAs and brain disorders.

167 **Mendelian randomization**

168 MR is a method in genetic epidemiology that uses SNPs as genetic instruments to
169 statistically infer causal associations between exposures and outcomes [61]. SNPs were
170 identified as being significantly associated with each exposure at the genome-wide significance
171 level ($P < 5 \times 10^{-8}$), and independent SNPs were derived using LD clumping ($r^2 < 0.001$ within a
172 10,000 kb window). For the primary analysis, the potential causal effects were estimated using a
173 multiplicative random-effect inverse weighted variance (IVW) model [62]. The MR-Egger
174 method was applied to detect and correct for possible pleiotropy, while a p -value > 0.05 in its
175 intercept test was used to rule out the presence of horizontal pleiotropic effects [63]. We also
176 used weighted median and weighted mode approaches to explore the robustness of our findings
177 in the presence of potential pleiotropy [64, 65]. As an additional sensitivity analysis against
178 pleiotropy, the MR-PRESSO method was performed to evaluate overall horizontal pleiotropy
179 and to re-calculate effect estimates after removing outlier SNPs [66]. A threshold of F -statistics $>$

180 10 indicates strong genetic instruments. Cochran Q-statistic was calculated to quantify the
181 heterogeneity among SNPs [67, 68]. Scatter plots, forest plots, and leave-one-out plots were
182 generated to visualize the effects of individual genetic instruments. To adjust for multiple testing,
183 we utilized the false-discovery rate (FDR) approach [69]. All analyses were performed using the
184 TwoSampleMR (v0.5.6) and MR-PRESSO (v1.0) packages in R [66, 70].

185 **Colocalization analysis**

186 We assessed the colocalization of genetic associations across traits using HyPrColoc
187 (v1.0) [71]. First, pairwise colocalization analyses were conducted for each pair of cPUFA and
188 brain disorder. We further performed multi-trait colocalization analysis for all cPUFAs and brain
189 disorders. We used the default prior probability that an SNP is associated with a single trait ($P =$
190 1×10^{-4}) and a conditional prior probability that an SNP is associated with an additional trait
191 given that it is already associated with another trait ($P_c = 0.02$). We defined a significant
192 colocalized region as a posterior probability (PP) > 0.7 . Regional association plots and
193 colocalization probability plots were generated with gassocplot (v0.14.0) R package, and LD
194 information was from 1KGP.

195 **Genome-wide statistical fine-mapping**

196 To statistically infer genetic variants that are causally associated with cPUFAs and brain
197 disorders, we performed genome-wide statistical fine-mapping with GWAS summary statistics
198 using SuSiE (v0.12.27). We first defined significant loci for each GWAS. Each significant locus
199 was determined as a region spanning 500kb above and below a top significant SNP ($P < 5 \times 10^{-8}$).
200 After defining one locus, we eliminated this locus, searched for the most significant SNP in the
201 remaining dataset, and defined the next locus. We iterated this process until no additional

202 significant locus was found. Note that some loci overlap with each other, and the inclusion of LD
203 information in the overlapped region is sometimes necessary for accurate fine-mapping. Since
204 samples of all cPUFA phenotypes and some brain disorders were obtained from UK Biobank, we
205 used LD matrices calculated based on 337,000 British-ancestry individuals in UK Biobank
206 (UKBB-LD) [72]. All LD matrices files were downloaded from
207 https://labs.icaahn.mssm.edu/minervalab/resources/data-ark/ukbb_ld/. We extracted pairwise
208 allelic LD correlations (r) for all SNPs in each defined locus. We summarized and reported 95%
209 credible sets (CS) of all significant loci. Additionally, we identified SNPs within the CS of the
210 cPUFAs and brain disorders dataset, which exhibited a posterior probability greater than 0.5 in at
211 least one dataset.

212 **Functional annotation and gene set enrichment analysis**

213 To assess the functional consequences of the potentially causal variants prioritized by
214 HyPrColoc and SuSiE, we used the Ensembl Variant Effect Predictor (VEP) [73] for functional
215 annotation, including their nearby genes, variant type and consequence, allele frequency in the
216 1KGP European sample, pathogenicity, and related phenotypes. Gene set enrichment analysis
217 was conducted for candidate genes using the FUMA [74] GENE2FUNC module. GTEx v8
218 RNA-seq data [75] was used to examine tissue-specific expression patterns of candidate genes.

219 **Data and code availability**

220 All GWAS summary statistics are publicly available as described above. All the code for
221 this study was uploaded to GitHub for public access (<https://github.com/Huifang-Xu/PUFA-BD>).

222 Results

223 Widespread, moderate genetic correlations between cPUFAs and brain disorders

224 Genetic correlations (r_g) between cPUFA phenotypes and brain disorders were estimated
225 using LDSC. Consistent with previous studies, there were strong genetic correlations between
226 cPUFAs [76] and between brain disorders [77-80] (**Supplementary Figure S2**). Widespread and
227 moderate genetic correlations were observed between 16 brain disorders and six cPUFA relative
228 measures, including PUFA%, omega-6%, LA%, omega-3%, DHA% and the omega-6:omega-3
229 ratio (**Figure 1A, Supplementary Figure S3 and Supplementary Table S3**). Out of the total
230 120 pairs, 77 pairs (64.2%) had $P < 0.05$ (average $|r_g| = 0.19$), 43 pairs (35.8%) had $P < 0.001$
231 (average $|r_g| = 0.23$), and 34 pairs (28.3%) showed significant genetic correlations after
232 Bonferroni correction ($P < 4.17 \times 10^{-4}$, average $|r_g| = 0.22$). Over 60% of the significant pairs
233 (48/77 pairs with $P < 0.05$ and 22/34 pairs with $P < 4.17 \times 10^{-4}$) showed negative correlations
234 between cPUFAs and brain disorders, suggesting that the shared genetic determinants are
235 associated with higher cPUFA levels but with reduced risks of brain disorders, such as NE and
236 PUFA% (**Figure 1C**).

237 PUFA%, omega-6%, omega-3%, LA%, and DHA% have significant negative correlation
238 with the following brain disorders, including the three substance use disorders (OD: $r_g = -0.23 \sim -$
239 0.40 , $P < 0.05$; AD: $r_g = -0.18 \sim -0.30$, $P < 0.05$; and CUD: $r_g = -0.20 \sim -0.27$, $P < 3 \times 10^{-4}$),
240 ADHD ($r_g = -0.22 \sim -0.33$, $P < 6.72 \times 10^{-6}$), PTSD ($r_g = -0.16 \sim -0.32$, $P < 0.05$), ANX ($r_g = -$
241 0.22 , $P < 0.05$), INS ($r_g = -0.12 \sim -0.20$, $P < 9 \times 10^{-4}$), MDD ($r_g = -0.10 \sim -0.19$, $P < 0.05$), and
242 NE ($r_g = -0.08 \sim -0.14$, $P < 0.01$; **Figure 1A and Supplementary Table S3**). In contrast, these
243 cPUFA measures are positively correlated with two disorders with compulsive behaviors (OCD:

244 $r_g = 0.14 \sim 0.30$, $P < 0.05$; AN: $r_g = 0.16 \sim 0.27$, $P < 6.50 \times 10^{-5}$). We did not observe any
245 significant genetic correlations between any cPUFAs and ALZ, MOOD, ASD, or TS, suggesting
246 that they share only a small proportion of common genetic components, or that the genetic
247 components they share have mixed effects on the two traits. It can also be partially explained by
248 insufficient statistical power due to small sample sizes of the GWAS of MOOD ($N_{\text{case}} = 1,546$)
249 and TS ($N_{\text{case}} = 4,819$).

250 **Widespread, moderate polygenic overlap between cPUFAs and brain disorders**

251 To quantify the polygenicity of and polygenic overlap between cPUFAs and brain
252 disorders, we applied the MiXeR univariate and bivariate Gaussian mixture models, respectively,
253 to their GWAS summary statistics. MiXeR statistically estimates the number of causal variants
254 needed to explain 90% of the SNP heritability of a trait without explicitly identifying the specific
255 variants. It also quantifies the number of shared causal variants between two traits (nc_{12}),
256 irrespective of their genetic correlation [59]. Five brain disorders (i.e., TS, OCD, ANX, OD and
257 AD) were not included in this analysis due to insufficient sample sizes.

258 All pairs of cPUFAs and brain disorders were statistically inferred to share causal variants,
259 although the degrees of sharing differ (**Figure 1B, Supplementary Figure S4 and**
260 **Supplementary Table S4**). They ranged from five variants between omega-3% and ALZ to 361
261 between PUFA% and MDD. PUFA% shared the greatest number of common variants ($nc_{12} = 37$ -
262 361) with brain disorders, while omega-3% shared the least number of common variants ($nc_{12} =$
263 5-33). Consistent with the findings of genetic correlation, 10 brain disorders (MDD, CUD, AN,
264 ADHD, NE, INS, SCZ, PTSD, AUDIT_C, and AUDIT_T) have strong polygenic overlaps with
265 multiple cPUFAs. For instance, PUFA% and NE have a strong negative genetic correlation ($r_g = -$
266 0.13 , $P = 2.0 \times 10^{-4}$) and a high level of polygenic overlap ($nc_{12} = 348$; **Figure 1C**), indicating

267 that most of the common variants shared between PUFA% and NE have opposite effect signs.
268 ALZ and cPUFAs share very low numbers of common variants. Interestingly, for some pairs of
269 cPUFAs and brain disorders, we observed no significant genetic correlations; however, they have
270 strong polygenic overlap, implying the presence of mixed effect directions among shared genetic
271 variants. For example, LA% does not have significant genetic correlation with AUDIT_C ($r_g =$
272 0.05 , $P = 0.28$), but they shared a moderate number of common variants ($nc_{12} = 131$). In addition,
273 we found that the genetic variants they share had mixed effects on the two traits (**Figure 1D**),
274 which explained why they had no significant genetic correlation but had strong polygenic
275 overlap.

276 The numbers of shared variants between cPUFA levels and brain disorders are limited by
277 the number of variants influencing cPUFAs. Compared with the strong polygenic overlap
278 between different brain disorders (mean $nc_{12} = 5,093$; **Supplementary Figure S5 and**
279 **Supplementary Table S5**), the average number of shared variants between cPUFAs is 76
280 (**Supplementary Figure S5**). We found that the number of shared variants is particularly limited
281 by the number of variants underlying each specific cPUFA. The average number of common
282 variants associated with cPUFA levels is 139, compared with 10,359 in brain disorders, a
283 difference of two orders of magnitude (**Figure 1B; Supplementary Table S4**). Our polygenic
284 overlap analysis revealed relatively simple genetic architecture of cPUFAs, high polygenicity of
285 brain disorders, and widespread, moderate polygenic overlap between the two groups of traits.

286 **Statistical inference of causal associations between cPUFAs and brain disorders**

287 To examine putative causal associations between six cPUFAs and 17 brain disorders, we
288 conducted bidirectional MR analyses using GWAS summary statistics. Three brain disorders

289 (AD, ALZ, and OD) were not included in the MR analysis due to the absence of effect sizes and
290 standard errors in their GWAS summary statistics.

291 We identified nine pairs, for which genetically predicted cPUFAs were significantly ($P <$
292 0.05) associated with increased risks of brain disorders; and seven pairs, for which genetically
293 predicted cPUFAs were associated with reduced risks of brain disorders (**Figure 2A-B and**
294 **Supplementary Table S7**). Among the 16 significant pairs identified in the forward MR analysis,
295 we did not detect any effect of brain disorders on cPUFA levels in our reverse MR analysis,
296 except for the pair of PUFA%-MDD (**Supplementary Figure S6 and Supplementary Table**
297 **S8**).

298 Among the 16 significant pairs, nine pairs presented consistent and strong evidence for
299 potential causal effects of cPUFAs on brain disorders when considering results from both genetic
300 correlation and MR (**Figure 1A and 2A**). Four pairs (omega-6%-CUD, PUFA%-MDD, omega-
301 3%-MDD, and DHA%-MDD) showed consistent negative associations, implying potential
302 protective effects of these cPUFAs against CUD and MDD. In contrast, five pairs (PUFA%-
303 AUDIT_C, omega-6%-AUDIT_C, PUFA%-AUDIT_T, omega-3%-AN, and omega-6:omega-3-
304 ADHD) showed consistent positive associations, indicating that these cPUFAs might increase the
305 risks of alcohol consumption, anorexia nervosa and ADHD.

306 Omega-3% were genetically predicted to be associated with a reduced risk of BIP. For a
307 one standard deviation (SD) increase in genetically predicted omega-3%, the odds ratio (OR) for
308 BIP was 0.91 (95% CI = [0.83, 1.00]) using the IVW method (**Figure 2C and Supplementary**
309 **Table S7**). Although horizontal pleiotropy was detected in the intercept test ($P_{\text{intercept}} = 0.043$),
310 the result remained significant after correcting for possible pleiotropy with the MR-Egger
311 approach (OR = 0.81, 95% CI = [0.70, 0.93]). The finding was consistent across other MR

312 methods. In the reverse MR, there was no evidence supporting a causal effect of BIP on omega-3%
313 ($\beta_{IVW} = -0.10$, 95% CI = [-0.33, 0.13]) (**Supplementary Table S8**).

314 **Prioritization of colocalized loci and shared variants**

315 To statistically prioritize genomic loci and infer causal variants responsible for both
316 cPUFA levels and brain disorders, we conducted pairwise colocalization analysis and statistical
317 fine-mapping. This analysis revealed 44 significant colocalized regions with a $PP > 0.7$ (**Figure**
318 **3A and Supplementary Table S9**). The 44 significant colocalized regions correspond to 13
319 unique regions. Furthermore, 22 unique SNPs were statistically inferred as potential causal
320 variants shared between cPUFAs and brain disorders, indicating that more than one variant
321 within these colocalized regions contribute to multiple trait pairs. Among the 22 unique SNPs, 14
322 were also included in 95% CSs defined by SuSiE (**Supplementary Table S9**). We also
323 performed multi-trait colocalization analysis combining all cPUFAs and brain disorders. We
324 identified four candidate shared SNPs (**Supplementary Table S9**).

325 To gain insights into the functional implications of the identified colocalized SNPs, we
326 annotated the nearest genes associated with the colocalized and fine-mapped SNPs using VEP
327 (**Supplementary Table S10**). Additionally, we performed gene set enrichment analysis using the
328 FUMA GENE2FUNC function [74]. This analysis revealed that the 36 prioritized genes are
329 significantly enriched in biological pathways related to lipid metabolism (FDR adjusted $P <$
330 0.05), providing further support for their potential biological relevance in the context of cPUFA
331 levels and brain disorders (**Supplementary Table S11**).

332 We highlight here one example that provides insights into the role of PUFAs on brain
333 disorders. The example involves BIP and all six cPUFA measures (**Figure 3B and 3C**), all of
334 which share a colocalized region at the *FADS* gene cluster (chr11:58,780,549-62,223,771).

335 Within this region, three distinct shared SNPs (i.e., rs174564, rs174567, rs174528) were
336 identified (**Supplementary Table S9**). To further investigate this region, we performed statistical
337 fine-mapping analysis using SuSiE, which supported the presence of multiple causal variants for
338 omega-3%, DHA%, PUFA% and omega-6:omega-3 (**Supplementary Figure S7**). This analysis
339 provided additional evidence for the potential involvement of multiple causal variants within the
340 *FADS* region in modulating the circulating levels of omega-3%, DHA%, PUFA%, and omega-
341 6:omega-3.

342 We also performed a multi-trait colocalization analysis combining these six cPUFA
343 phenotypes with BIP. The variant rs174564 (chr11:61588305A>G) had the highest PP of 0.95
344 (**Figure 3C**), suggesting that it is likely the shared causal variant between cPUFAs and BIP. The
345 SNP is an intronic variant of the *FADS2* gene and is known to be associated with both cPUFA
346 levels and BIP. The A allele of rs174564 was associated with an increased level of DHA% ($\beta =$
347 0.28 , $SE = 0.004$, $P < 1 \times 10^{-300}$) and omega-3% ($\beta = 0.39$, $SE = 0.004$, $P < 1 \times 10^{-300}$), while
348 with a reduced risk of BIP ($OR = 0.93$, $95\% \text{ CI} = [0.91, 0.95]$, $P = 6.24 \times 10^{-13}$). Furthermore,
349 MR analysis also revealed a negative association between omega-3% and BIP (**Figure 2A-C**).
350 Combining the results of MR and colocalization analysis, there is strong evidence supporting that
351 omega-3% has a protective effect on bipolar disorder.

352 **Potential causal relationships informed by shared genetic basis**

353 To advance our understanding of the potential causal relationship between cPUFAs and
354 brain disorders, we compared and synthesized the findings across the multiple approaches of
355 evaluating shared genetic basis. We designated strong evidence supporting a potential causal
356 relationship when there are statistically significant and directionally consistent results in genetic
357 correlation ($P < 0.05$), MR ($P < 0.05$), and colocalization ($PP > 0.7$). We did not include

358 polygenic overlap due to its ubiquity among all six cPUFA phenotypes and brain disorders. We
359 considered that there is suggestive evidence when there were statistically significant and
360 directionally consistent results in genetic correlation ($P < 0.05$) and colocalization ($PP > 0.7$).

361 We identified four pairs with strong evidence supporting potential causal effects of the
362 specific cPUFAs on the corresponding brain disorders (**Table 1**). For example, PUFA% is likely
363 to have protective effect on MDD with support from the following evidence: 1) PUFA% showed
364 a negative genetic correlation with MDD ($r_g = -0.19$, $P = 7.14 \times 10^{-16}$); 2) MR results suggest
365 that higher PUFA% is associated with a reduced risk of MDD (OR = 0.95, 95% CI = [0.92, 0.99],
366 $P = 5.76 \times 10^{-3}$); 3) Colocalization analysis identified a colocalized region at chr21q22.3
367 (chr21:46,177,105-47,492,226; PP = 0.83) and a potential shared causal variant rs4818766
368 (chr21:46635351A>G), which is an intronic variant of gene *ADARBI*. SNP rs4818766 is known
369 to be associated with body fat distribution [81]. *ADARBI* is highly expressed in the brain and
370 related to developmental and epileptic encephalopathy [82] and psychiatric disorders [83, 84]. In
371 addition to PUFA%, our forward MR results also show that higher levels of omega-3% and DHA%
372 were associated with a reduced risk of MDD, in line with a recent finding [23]. Interestingly, our
373 forward and reverse MR both showed negative associations between PUFA% and MDD
374 (forward MR: OR = 0.95, 95% CI = [0.92, 0.99], $P = 5.76 \times 10^{-3}$; reverse MR: OR = 0.91, 95%
375 CI = [0.84, 0.99], $P = 0.013$), driven by different genetic variants (**Supplementary Figure S8**),
376 supporting a potential bidirectional relationship.

377 We also found that lower omega-6% are related to lower alcohol consumption (**Table 1**).
378 Both genetic correlation ($r_g = 0.08$, $P = 0.036$; **Figure 4A**) and forward MR results ($\beta_{IVW} = 0.019$,
379 $P = 0.001$; **Figure 4B**) revealed a positive association between omega-6% and alcohol
380 consumption. In our colocalization analysis (**Figure 4C and 4D**), we observed that genomic

381 region 2p23.2-2p23.3 (chr2:26,894,985-28,598,777) exhibited colocalization signals among
382 three alcohol-intake phenotypes (AUDIT_C, AUDIT_T, AUDIT_P) and five cPUFA phenotypes
383 (omega-3%, omega-6%, LA%, PUFA% and omega-6:omega-3). Within this region, SNP
384 rs1260326 (chr2:27730940T>C) was identified as a potential shared causal variant (PP = 0.99).
385 Notably, the T allele of rs1260326 was associated with lower levels of omega-6% ($\beta = -0.11$, SE
386 = 0.004, $P = 7.0 \times 10^{-159}$), LA% ($\beta = -0.08$, SE = 0.004, $P = 1.20 \times 10^{-87}$) and lower alcohol
387 consumption (AUDIT_C: $\beta = -0.007$, SE = 0.001, $P = 5.47 \times 10^{-9}$; AUDIT_T: $\beta = -0.008$, SE =
388 0.001, $P = 2.11 \times 10^{-10}$; AUDIT_P: $\beta = -0.005$, SE = 0.001, $P = 6.7 \times 10^{-7}$). SNP rs1260326, a
389 missense variant for gene *GCKR*, is known to be associated with alcohol intake [85], type 2
390 diabetes [86], liver diseases [87, 88] and lipid levels such as triglyceride and cholesterol [89].
391 Taken together evidence from genetic correlation, MR and colocalization analysis, our findings
392 indicate that lower omega-6% may lower alcohol consumption.

393 We identified eight trait pairs that display suggestive evidence for a potential causal
394 relationship. Interestingly, our genetic correlation analysis unveiled a negative correlation
395 between ADHD and three cPUFA phenotypes: PUFA% ($r_g = -0.3$, $P = 2.51 \times 10^{-12}$), omega-6%
396 ($r_g = -0.25$, $P = 5.67 \times 10^{-8}$), and DHA% ($r_g = -0.32$, $P = 1.73 \times 10^{-10}$). Further colocalization
397 analysis identified a genomic locus chr9:85,440,801-86,938,196 shared among ADHD, PUFA%,
398 omega-6% and LA% (PP > 0.7; **Table 1**). Our forward MR did not reveal significant associations
399 between ADHD and the three cPUFAs. However, the reverse MR displayed significant negative
400 associations (PUFA%: $\beta_{IVW} = -0.07$, $P = 3.48 \times 10^{-3}$; omega-6%: $\beta_{IVW} = -0.05$, $P = 0.046$; and
401 DHA%: $\beta_{IVW} = -0.08$, $P = 3.43 \times 10^{-3}$; **Supplementary Table S8**), suggesting that the presence
402 of ADHD might contribute to decreased circulating PUFA levels. These findings align with
403 previous research indicating that individuals with ADHD generally exhibit lower omega-3 PUFA

404 levels compared to the control group [14]. This ADHD example provides clues for further studies
405 into the intricate relationship between ADHD and cPUFAs.

406 Discussion

407 By leveraging GWAS summary statistics of six cPUFA phenotypes and 20 brain disorders,
408 we revealed a widespread shared genetic basis between the two groups of traits. Our MR analysis
409 found 16 pairs of cPUFAs and brain disorders that display potential causal associations. Further
410 colocalization and fine-mapping analysis led to statistically inferred candidate shared causal
411 variants, such as rs1260326 (*GCKR*), rs174564 (*FADS2*) and rs4818766 (*ADARB1*). We also
412 identified cPUFA-brain disorder pairs with consistent results across various analysis approaches,
413 emphasizing a prominent role of cPUFAs in brain disorders, especially MDD, BIP and alcohol
414 consumption-related phenotypes. Our discoveries provide novel insights into the intricate
415 relationships between cPUFAs and brain disorders, improving our knowledge in refining dietary
416 strategies for prevention and intervention.

417 The protective effect of PUFA% on MDD is strongly supported by various methods with
418 different model assumptions, including genetic correlation, MR and colocalization. We identified
419 a putative shared variant rs4818766 and a candidate gene *ADARB1*. *ADARB1* encodes one of the
420 enzymes involved in the adenosine-to-inosine (A-to-I) RNA editing process known as Adenosine
421 Deaminases Acting on RNA (ADAR2) [90]. One of the leading hypotheses regarding the
422 pathogenicity of MDD is the serotonin hypothesis, which suggests that depression may arise
423 from abnormalities in neurotransmitters, particularly serotonin [90, 91]. ADAR2 could edit
424 serotonin 2C receptor (5-HT_{2c}-R) at the D site, which reduces G protein coupling and affinity for
425 serotonin [90]. Notably, prior research has shown that ADAR2 knock-out and mutant mice
426 lacking the deaminase activity of ADAR2 exhibit elevated body fat and reduced ability to utilize
427 fatty acids [92, 93]. Animal studies have also demonstrated that supplementing PUFAs in rats

428 leads to higher concentrations of serotonin in the brain [94]. Taken together, it is plausible that
429 PUFAs reduce the risk of MDD by modulating the serotonin transportation through ADAR2 [95].

430 Our study also supports the protective effect of omega-3% on BIP. MR analysis showed
431 that higher omega-3% are associated with a reduced risk of bipolar disorder. Further
432 colocalization analysis identified a colocalized region where the *FADS1* and *FADS2* genes are
433 located. Statistically inferred shared causal variant rs174564 is an intronic variant of the *FADS2*
434 gene. SNPs in the *FADS1/2* region have been reported to be associated with circulating PUFA
435 levels and the risk of bipolar disorder in different populations [28, 96, 97]. Significant changes in
436 the lipid profiles of the plasma and brain, as well as behavioral changes (e.g., hyperactivity and
437 hypoactivity episodes), were observed in heterozygous *Fads1/2* knockout mice [24]. Moreover,
438 dietary DHA supplementation reduced depressive episodes in the mutant mice, supporting the
439 protective role of omega-3% against BIP.

440 We show that lower levels of omega-6% are related to lower alcohol consumption. We
441 statistically inferred a shared causal variant rs1260326 (gene: *GCKR*), which explains a
442 colocalized association signal between omega-6% levels and alcohol consumption. *GCKR*
443 encodes glucokinase regulatory protein that binds to glucokinase. Compared to the C allele of
444 rs1260326, the T allele results in lower binding efficiency of glucokinase regulatory protein,
445 leading to increased total fatty acids formation, liver fat and triglyceride accumulation [98]. In
446 addition, the T allele is linked to a higher risk of liver diseases, including nonalcoholic fatty liver
447 disease (NAFLD) and non-alcoholic steatohepatitis [99]. Lower serum levels of omega-6 fatty
448 acids and LA were associated with a higher risk for NAFLD [100]. Taken together, it is possible
449 that individuals with lower PUFA and omega-6 levels tend to have more liver problems (e.g.,

450 accumulation of liver fat, elevated levels of triglyceride, and alanine aminotransferase), and thus
451 tend to drink less.

452 We note that disease status itself might influence cPUFA levels. Our reverse MR results
453 revealed a significant negative association between ADHD and three cPUFAs (PUFA%, omega-6%
454 and LA%), suggesting that altered cPUFA levels may be one of the metabolic consequences of
455 ADHD. Further pairwise colocalization analysis identified a region chr9:85,440,801-86,938,196
456 colocalized among ADHD, PUFA%, omega-6% and LA% (**Table 1** and **Supplementary Table**
457 **S9**). Three distinct SNPs (i.e., rs2576362, rs1982151, rs6559744) were statistically inferred as
458 putative causal variants that explain the shared association signal. However, none of the
459 identified SNP has strong enough evidence for causation ($PP < 0.1$), and further studies are
460 needed to pinpoint shared causal variants and candidate genes in this region.

461 The discrepancy between the genetic correlation and MR results could be attributed to the
462 differences in the sets of genetic variants analyzed in either approach and the existence of
463 discordant pleiotropy across variants. It also reflects the limitations of different methods as well
464 as the complex genetic architecture of brain disorders [101]. Taking omega-3% and BIP as an
465 example, their positive genetic correlation suggests the presence of a substantial number of
466 common variants that exert small yet consistent effects on both phenotypes (**Supplementary**
467 **Figure S9**). However, the negative association observed in MR and colocalization analysis is
468 driven by the *FADS* locus that exhibited a relatively large effect but with opposite directions on
469 the two phenotypes (**Supplementary Figure S8** and **Supplementary Table S12**). We highlight
470 the need to understand the biological function of genetic variants in MR analysis, especially
471 when the trait of interest has complicated genetic architecture [101, 102].

472 In our analysis, we focused on relative measures of cPUFAs. We found limited genetic
473 correlations or polygenic overlaps between the absolute measures of cPUFAs and brain disorders
474 (**Supplementary Figure S3-S4 and Table S3-S4**). It is important to note that absolute and
475 relative measures of cPUFAs offer distinct perspectives on fatty acid metabolism. Relative
476 measures are preferred in the majority of cases because PUFAs as well as saturated and
477 monounsaturated fatty acids are metabolized by the same enzymes derived from common genes
478 (e.g. *FADS1/FADS2*) [103]. They are also preferred because relative measures are more precise
479 (lower analytical SDs) since they are all referenced to one another and not to exogenously-added
480 internal standards. Absolute measures provide direct information about the quantities of cPUFAs
481 which become important when any particular fatty acid may become limiting for a particular
482 physiological requirement [104-106]. The different patterns with brain disorders are consistent
483 with the limited genetic correlation between absolute and relative cPUFAs (**Supplementary**
484 **Figure S2**). They likely reflect different aspects of lipid metabolism. Future studies are needed to
485 discern the exact mechanisms.

486 Our study is not without limitations. First, using different GWAS summary statistics
487 could lead to minor differences in the results since slightly different analytical strategies were
488 applied (e.g., association methods, quality control criteria, and covariates). To address this issue,
489 we analyzed multiple GWAS of the same phenotype to evaluate robustness of our discoveries.
490 We observed consistent correlation patterns with different GWAS of the same traits
491 (**Supplementary Figure S3 and Supplementary Table S3**). Second, five brain disorders (i.e.,
492 ANX, OCD, OD, AD, and TS) had relatively small sample sizes that did not meet the
493 requirement of MiXeR and were therefore excluded from the estimation of polygenic overlap.
494 Finally, our study focused only on the European population. Genetic adaptation and variation of

495 fatty acid composition have been demonstrated in the Inuit, African, South Asian, East Asian,
496 and European populations [23, 107-109]. Differences in prevalence [110, 111] and genetic risk
497 factors [89] of psychiatric disorders were also demonstrated across ethnic groups. Therefore,
498 expanding our research to other populations is necessary to gain a deeper understanding of the
499 shared genetic basis and genetic determinants between cPUFAs and brain disorders across
500 populations.

501 Our systemic genetic analysis of six cPUFA traits and 20 brain disorders uncovered a
502 widespread shared genetic basis between the two groups. We pinpointed specific shared genetic
503 variants and provided evidence supporting the potential effects of certain cPUFAs on specific
504 brain disorders. Our findings provide new insights into the shared genetic architecture underlying
505 these traits and have implications for interventions and dietary recommendations of PUFAs in the
506 context of brain disorders.

507 **Supplemental information description**

508 Figure S1. Flowchart of the study

509 Figure S2. Pairwise genetic correlations A) between brain disorders and B) between cPUFA
510 phenotypes.

511 Figure S3. Pairwise genetic correlations between cPUFAs and brain disorders

512 Figure S4. Pairwise polygenic overlaps between cPUFAs and brain disorders

513 Figure S5. Pairwise polygenic overlaps A) between brain disorders and B) between cPUFAs.

514 Figure S6. Reverse MR results

515 Figure S7. Statistical fine-mapping posterior inclusion probability plots in 11q12.1-11q12.3 for A)
516 omega-3%, B) DHA%, C) PUFA% and D) omega-6:omega-3

517 Figure S8. Bidirectional association between PUFA% and MDD

518 Figure S9. Differences in the SNP sets in omega-3%-BIP genetic correlation and MR analysis

519 Table S1. Literature review on PUFA-brain disorders Mendelian randomization studies

520 Table S2. Dataset characteristics

521 Table S3. Pairwise genetic correlations between cPUFAs and brain disorders

522 Table S4. MiXeR univariate estimates and bivariate estimates between cPUFAs and brain
523 disorders

524 Table S5. MiXeR bivariate estimates between brain disorders

525 Table S6. MiXeR bivariate estimates between cPUFAs

526 Table S7. Forward MR results inferring the causal effect of cPUFAs on brain disorders

527 Table S8. Reverse MR results inferring the causal effect of brain disorders on cPUFAs levels

528 Table S9. Pairwise colocalization analysis and fine-mapping results

529 Table S10. Functional annotation of colocalized and fine-mapped SNPs by VEP

530 Table S11. Gene-set enrichment analysis of 36 candidate genes using FUMA GENE2FUNC

531 Table S12. Genetic instruments included in the omega-3%-BIP MR analysis

532 Abbreviations

1KGP	1000 Genomes Project
AD	Alcohol dependence
ADARB1	Adenosine Deaminase RNA Specific B1
ADHD	Attention deficit-hyperactivity disorder
ALZ	Alzheimer's disease
AN	Anorexia nervosa
ANX	Anxiety disorders and factors
ASD	Autism spectrum disorder
AUDIT	Alcohol use disorder identification test
AUDIT_C	AUDIT focusing on alcohol consumption
AUDIT_P	AUDIT focusing on the problematic consequences of drinking
AUDIT_T	AUDIT total score
BIP	Bipolar disorder
cPUFA	Circulating polyunsaturated fatty acids
CS	Credible set
CUD	Cannabis use disorder
DHA	Docosahexaenoic acid
FADS	Fatty acid desaturase
GCKR	Glucokinase regulatory protein
GWAS	Genome-wide association study
h^2	Heritability
INS	Insomnia
IVW	Inverse weighted variance
LA	Linoleic acid
LD	Linkage disequilibrium
LDSC	LD Score regression
MAF	Minor allele frequency
MDD	Major depression
MHC	Major histocompatibility complex
MOOD	Mood disorders
MR	Mendelian randomization
NAFLD	Nonalcoholic fatty liver disease
nc12	Number of common variants shared between trait1 and trait2
NE	Neuroticism
OCD	Obsessive-compulsive disorder
OD	Opioid dependence
PGC	Psychiatric Genomic Consortium
PP	Posterior probability
PTSD	Post-traumatic stress disorder
PUFA	Polyunsaturated fatty acids
r_g	Genetic correlation coefficient

SCZ	Schizophrenia
SNP	Single-nucleotide polymorphism
TS	Tourette syndrome
VEP	Variant Effect Predictor

533

534 **Acknowledgements**

535 Research reported in this publication was supported by the National Institute Of General
536 Medical Sciences of the National Institutes of Health under Award Number R35GM143060. The
537 content is solely the responsibility of the authors and does not necessarily represent the official
538 views of the National Institutes of Health. We thank the PGC, IEU Open GWAS, and CNCR for
539 providing access to genome-wide association study data. We also thank all research participants
540 who provided DNA samples for these studies. We thank the UGA GACRC staff for facilitating
541 our data analysis.

542

543 **Conflict of Interest**

544 The authors report no conflicts of interest.

545

546 **Author contributions**

547 K.Y. conceptualized and supervised the study. K.Y., H.X., and Y.S. designed the analysis.
548 H.X. collected data. H.X. and Y.S. performed most data analysis with assistance from M.F.,
549 N.T.R.M., and C.F.C.. H.X., Y.S., K.Y., J.T.B., and C.W.K.C. interpreted the results and wrote the
550 manuscript. All authors reviewed, revised, and approved the manuscript.

551 References

- 552 1. Diseases, G.B.D. and C. Injuries, *Global burden of 369 diseases and injuries in 204*
553 *countries and territories, 1990-2019: a systematic analysis for the Global Burden of*
554 *Disease Study 2019*. Lancet, 2020. **396**(10258): p. 1204-1222.
- 555 2. Collaborators, G.B.D.M.D., *Global, regional, and national burden of 12 mental disorders*
556 *in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden*
557 *of Disease Study 2019*. Lancet Psychiatry, 2022. **9**(2): p. 137-150.
- 558 3. Bradvik, L., *Suicide Risk and Mental Disorders*. Int J Environ Res Public Health, 2018.
559 **15**(9).
- 560 4. Sarris, J., et al., *Nutritional medicine as mainstream in psychiatry*. The Lancet Psychiatry,
561 2015. **2**(3): p. 271-274.
- 562 5. Firth, J., et al., *The efficacy and safety of nutrient supplements in the treatment of*
563 *mental disorders: a meta-review of meta-analyses of randomized controlled trials*. World
564 Psychiatry, 2019. **18**(3): p. 308-324.
- 565 6. Bazinet, R.P. and S. Layé, *Polyunsaturated fatty acids and their metabolites in brain*
566 *function and disease*. Nature Reviews Neuroscience, 2014. **15**(12): p. 771-785.
- 567 7. Brenna, J.T., *Animal studies of the functional consequences of suboptimal*
568 *polyunsaturated fatty acid status during pregnancy, lactation and early post-natal life*.
569 Matern Child Nutr, 2011. **7 Suppl 2**(Suppl 2): p. 59-79.
- 570 8. Melo, H.M., L.E. Santos, and S.T. Ferreira, *Diet-Derived Fatty Acids, Brain Inflammation,*
571 *and Mental Health*. Front Neurosci, 2019. **13**: p. 265.
- 572 9. Lin, P.Y., S.Y. Huang, and K.P. Su, *A meta-analytic review of polyunsaturated fatty acid*
573 *compositions in patients with depression*. Biol Psychiatry, 2010. **68**(2): p. 140-7.
- 574 10. Liao, Y., et al., *Efficacy of omega-3 PUFAs in depression: A meta-analysis*. Transl
575 Psychiatry, 2019. **9**(1): p. 190.
- 576 11. Thesing, C.S., et al., *Omega-3 and omega-6 fatty acid levels in depressive and anxiety*
577 *disorders*. Psychoneuroendocrinology, 2018. **87**: p. 53-62.
- 578 12. Amminger, G.P., et al., *Long-chain omega-3 fatty acids for indicated prevention of*
579 *psychotic disorders: a randomized, placebo-controlled trial*. Arch Gen Psychiatry, 2010.
580 **67**(2): p. 146-54.
- 581 13. Amminger, G.P., et al., *Longer-term outcome in the prevention of psychotic disorders by*
582 *the Vienna omega-3 study*. Nat Commun, 2015. **6**: p. 7934.
- 583 14. Chang, J.P., et al., *Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit*
584 *Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and*
585 *Biological Studies*. Neuropsychopharmacology, 2018. **43**(3): p. 534-545.
- 586 15. Mazahery, H., et al., *Relationship between long chain n-3 polyunsaturated fatty acids*
587 *and autism spectrum disorder: systematic review and meta-analysis of case-control and*
588 *randomised controlled trials*. Nutrients, 2017. **9**(2): p. 155.
- 589 16. Cederholm, T., N. Salem Jr, and J. Palmblad, *ω -3 fatty acids in the prevention of cognitive*
590 *decline in humans*. Advances in nutrition, 2013. **4**(6): p. 672-676.
- 591 17. Deane, K.H.O., et al., *Omega-3 and polyunsaturated fat for prevention of depression and*
592 *anxiety symptoms: systematic review and meta-analysis of randomised trials*. Br J
593 Psychiatry, 2021. **218**(3): p. 135-142.

- 594 18. Mazereeuw, G., et al., *Effects of omega-3 fatty acids on cognitive performance: a meta-*
595 *analysis*. *Neurobiol Aging*, 2012. **33**(7): p. 1482 e17-29.
- 596 19. McGorry, P.D., et al., *Effect of ω -3 polyunsaturated fatty acids in young people at*
597 *ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial*. *JAMA*
598 *psychiatry*, 2017. **74**(1): p. 19-27.
- 599 20. Cheng, N., et al., *Effects of omega-3 polyunsaturated fatty acid supplementation on*
600 *cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the*
601 *NEURAPRO randomised controlled trial*. *BJPsych open*, 2022. **8**(5): p. e165.
- 602 21. Ioannidis, J.P.A., *The Challenge of Reforming Nutritional Epidemiologic Research*. *JAMA*,
603 2018. **320**(10): p. 969-970.
- 604 22. van Rheenen, W., et al., *Genetic correlations of polygenic disease traits: from theory to*
605 *practice*. *Nat Rev Genet*, 2019. **20**(10): p. 567-581.
- 606 23. Davyson, E., et al., *Metabolomic Investigation of Major Depressive Disorder Identifies a*
607 *Potentially Causal Association With Polyunsaturated Fatty Acids*. *Biol Psychiatry*, 2023.
- 608 24. Yamamoto, H., et al., *GWAS-identified bipolar disorder risk allele in the FADS1/2 gene*
609 *region links mood episodes and unsaturated fatty acid metabolism in mutant mice*. *Mol*
610 *Psychiatry*, 2023.
- 611 25. Milaneschi, Y., et al., *A role for vitamin D and omega-3 fatty acids in major depression?*
612 *An exploration using genomics*. *Transl Psychiatry*, 2019. **9**(1): p. 219.
- 613 26. Jones, H.J., et al., *Associations between plasma fatty acid concentrations and*
614 *schizophrenia: a two-sample Mendelian randomisation study*. *The Lancet Psychiatry*,
615 2021. **8**(12): p. 1062-1070.
- 616 27. Gao, Y., et al., *Association between Arachidonic Acid and the Risk of Schizophrenia: A*
617 *Cross-National Study and Mendelian Randomization Analysis*. *Nutrients*, 2023. **15**(5): p.
618 1195.
- 619 28. Zhao, L., et al., *Replicated associations of FADS1, MAD1L1, and a rare variant at 10q26.*
620 *13 with bipolar disorder in Chinese population*. *Translational Psychiatry*, 2018. **8**(1): p.
621 270.
- 622 29. Schizophrenia Working Group of the Psychiatric Genomics, C., *Biological insights from*
623 *108 schizophrenia-associated genetic loci*. *Nature*, 2014. **511**(7510): p. 421-7.
- 624 30. Howard, D.M., et al., *Genome-wide meta-analysis of depression identifies 102*
625 *independent variants and highlights the importance of the prefrontal brain regions*. *Nat*
626 *Neurosci*, 2019. **22**(3): p. 343-352.
- 627 31. Mullins, N., et al., *Genome-wide association study of more than 40,000 bipolar disorder*
628 *cases provides new insights into the underlying biology*. *Nature genetics*, 2021. **53**(6): p.
629 817-829.
- 630 32. International Obsessive Compulsive Disorder Foundation Genetics, C. and O.C.D.C.G.A.
631 *Studies, Revealing the complex genetic architecture of obsessive-compulsive disorder*
632 *using meta-analysis*. *Mol Psychiatry*, 2018. **23**(5): p. 1181-1188.
- 633 33. Otowa, T., et al., *Meta-analysis of genome-wide association studies of anxiety disorders*.
634 *Mol Psychiatry*, 2016. **21**(10): p. 1485.
- 635 34. Nievergelt, C.M., et al., *International meta-analysis of PTSD genome-wide association*
636 *studies identifies sex- and ancestry-specific genetic risk loci*. *Nat Commun*, 2019. **10**(1): p.
637 4558.

- 638 35. Watson, H.J., et al., *Genome-wide association study identifies eight risk loci and*
639 *implicates metabo-psychiatric origins for anorexia nervosa*. *Nat Genet*, 2019. **51**(8): p.
640 1207-1214.
- 641 36. Grove, J., et al., *Identification of common genetic risk variants for autism spectrum*
642 *disorder*. *Nat Genet*, 2019. **51**(3): p. 431-444.
- 643 37. Yu, D., et al., *Interrogating the genetic determinants of Tourette's syndrome and other tic*
644 *disorders through genome-wide association studies*. *American Journal of Psychiatry*,
645 2019. **176**(3): p. 217-227.
- 646 38. Demontis, D., et al., *Discovery of the first genome-wide significant risk loci for attention*
647 *deficit/hyperactivity disorder*. *Nat Genet*, 2019. **51**(1): p. 63-75.
- 648 39. Watanabe, K., et al., *Genome-wide meta-analysis of insomnia prioritizes genes*
649 *associated with metabolic and psychiatric pathways*. *Nat Genet*, 2022. **54**(8): p. 1125-
650 1132.
- 651 40. Werme, J., et al., *Genome-wide gene-environment interactions in neuroticism: an*
652 *exploratory study across 25 environments*. *Transl Psychiatry*, 2021. **11**(1): p. 180.
- 653 41. Wightman, D.P., et al., *A genome-wide association study with 1,126,563 individuals*
654 *identifies new risk loci for Alzheimer's disease*. *Nat Genet*, 2021. **53**(9): p. 1276-1282.
- 655 42. Polimanti, R., et al., *Leveraging genome-wide data to investigate differences between*
656 *opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics*
657 *Consortium*. *Molecular psychiatry*, 2020. **25**(8): p. 1673-1687.
- 658 43. Johnson, E.C., et al., *A large-scale genome-wide association study meta-analysis of*
659 *cannabis use disorder*. *Lancet Psychiatry*, 2020. **7**(12): p. 1032-1045.
- 660 44. Walters, R.K., et al., *Transancestral GWAS of alcohol dependence reveals common*
661 *genetic underpinnings with psychiatric disorders*. *Nat Neurosci*, 2018. **21**(12): p. 1656-
662 1669.
- 663 45. Sanchez-Roige, S., et al., *Genome-Wide Association Study Meta-Analysis of the Alcohol*
664 *Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts*. *Am J*
665 *Psychiatry*, 2019. **176**(2): p. 107-118.
- 666 46. Lyon, M.S., et al., *The variant call format provides efficient and robust storage of GWAS*
667 *summary statistics*. *Genome Biol*, 2021. **22**(1): p. 32.
- 668 47. Sullivan, P.F., et al., *Psychiatric Genomics: An Update and an Agenda*. *Am J Psychiatry*,
669 2018. **175**(1): p. 15-27.
- 670 48. Pardini, A.F., et al., *Common schizophrenia alleles are enriched in mutation-intolerant*
671 *genes and in regions under strong background selection*. *Nat Genet*, 2018. **50**(3): p. 381-
672 389.
- 673 49. Duncan, L.E., et al., *Largest GWAS of PTSD (N=20 070) yields genetic overlap with*
674 *schizophrenia and sex differences in heritability*. *Mol Psychiatry*, 2018. **23**(3): p. 666-673.
- 675 50. Forstner, A.J., et al., *Genome-wide association study of panic disorder reveals genetic*
676 *overlap with neuroticism and depression*. *Mol Psychiatry*, 2021. **26**(8): p. 4179-4190.
- 677 51. Neale, B.M., et al., *Meta-analysis of genome-wide association studies of attention-*
678 *deficit/hyperactivity disorder*. *J Am Acad Child Adolesc Psychiatry*, 2010. **49**(9): p. 884-97.
- 679 52. Hinrichs, A.S., et al., *The UCSC Genome Browser Database: update 2006*. *Nucleic Acids*
680 *Res*, 2006. **34**(Database issue): p. D590-8.

- 681 53. Murphy, A.E., B.M. Schilder, and N.G. Skene, *MungeSumstats: A Bioconductor package*
682 *for the standardisation and quality control of many GWAS summary statistics.*
683 *Bioinformatics*, 2021. **37**(23): p. 4593-6.
- 684 54. Bulik-Sullivan, B.K., et al., *LD Score regression distinguishes confounding from*
685 *polygenicity in genome-wide association studies.* *Nat Genet*, 2015. **47**(3): p. 291-5.
- 686 55. Bulik-Sullivan, B., et al., *An atlas of genetic correlations across human diseases and traits.*
687 *Nat Genet*, 2015. **47**(11): p. 1236-41.
- 688 56. Genomes Project, C., et al., *A global reference for human genetic variation.* *Nature*, 2015.
689 **526**(7571): p. 68-74.
- 690 57. Wei, T., et al., *package 'corrplot': visualization of a correlation matrix (Version 0.92).*
691 2021. 2022.
- 692 58. Holland, D., et al., *Beyond SNP heritability: Polygenicity and discoverability of phenotypes*
693 *estimated with a univariate Gaussian mixture model.* *PLoS Genetics*, 2020. **16**(5): p.
694 e1008612.
- 695 59. Frei, O., et al., *Bivariate causal mixture model quantifies polygenic overlap between*
696 *complex traits beyond genetic correlation.* *Nature communications*, 2019. **10**(1): p. 2417.
- 697 60. Gu, Z., R. Eils, and M. Schlesner, *Complex heatmaps reveal patterns and correlations in*
698 *multidimensional genomic data.* *Bioinformatics*, 2016. **32**(18): p. 2847-9.
- 699 61. Davey Smith, G. and S. Ebrahim, *'Mendelian randomization': can genetic epidemiology*
700 *contribute to understanding environmental determinants of disease?* *International*
701 *journal of epidemiology*, 2003. **32**(1): p. 1-22.
- 702 62. Burgess, S., A. Butterworth, and S.G. Thompson, *Mendelian randomization analysis with*
703 *multiple genetic variants using summarized data.* *Genet Epidemiol*, 2013. **37**(7): p. 658-
704 65.
- 705 63. Bowden, J., G. Davey Smith, and S. Burgess, *Mendelian randomization with invalid*
706 *instruments: effect estimation and bias detection through Egger regression.* *International*
707 *journal of epidemiology*, 2015. **44**(2): p. 512-525.
- 708 64. Bowden, J., et al., *Consistent estimation in Mendelian randomization with some invalid*
709 *instruments using a weighted median estimator.* *Genetic epidemiology*, 2016. **40**(4): p.
710 304-314.
- 711 65. Hartwig, F.P., G. Davey Smith, and J. Bowden, *Robust inference in summary data*
712 *Mendelian randomization via the zero modal pleiotropy assumption.* *Int J Epidemiol*,
713 2017. **46**(6): p. 1985-1998.
- 714 66. Verbanck, M., et al., *Detection of widespread horizontal pleiotropy in causal relationships*
715 *inferred from Mendelian randomization between complex traits and diseases.* *Nature*
716 *genetics*, 2018. **50**(5): p. 693-698.
- 717 67. Greco, M.F., et al., *Detecting pleiotropy in Mendelian randomisation studies with*
718 *summary data and a continuous outcome.* *Stat Med*, 2015. **34**(21): p. 2926-40.
- 719 68. Bowden, J., et al., *Improving the visualization, interpretation and analysis of two-sample*
720 *summary data Mendelian randomization via the Radial plot and Radial regression.* *Int J*
721 *Epidemiol*, 2018. **47**(4): p. 1264-1278.
- 722 69. Korthauer, K., et al., *A practical guide to methods controlling false discoveries in*
723 *computational biology.* *Genome Biol*, 2019. **20**(1): p. 118.

- 724 70. Hemani, G., et al., *The MR-Base platform supports systematic causal inference across the*
725 *human phenome*. *Elife*, 2018. **7**.
- 726 71. Foley, C.N., et al., *A fast and efficient colocalization algorithm for identifying shared*
727 *genetic risk factors across multiple traits*. *Nat Commun*, 2021. **12**(1): p. 764.
- 728 72. Weissbrod, O., et al., *Functionally informed fine-mapping and polygenic localization of*
729 *complex trait heritability*. *Nat Genet*, 2020. **52**(12): p. 1355-1363.
- 730 73. McLaren, W., et al., *The Ensembl Variant Effect Predictor*. *Genome Biol*, 2016. **17**(1): p.
731 122.
- 732 74. Watanabe, K., et al., *Functional mapping and annotation of genetic associations with*
733 *FUMA*. *Nat Commun*, 2017. **8**(1): p. 1826.
- 734 75. Consortium, G.T., *Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis:*
735 *multitissue gene regulation in humans*. *Science*, 2015. **348**(6235): p. 648-60.
- 736 76. Francis, M., et al., *Fifty-one novel and replicated GWAS loci for polyunsaturated and*
737 *monounsaturated fatty acids in 124,024 Europeans*. *medRxiv*, 2022: p. 2022.05.
738 27.22275343.
- 739 77. Brainstorm, C., et al., *Analysis of shared heritability in common disorders of the brain*.
740 *Science*, 2018. **360**(6395).
- 741 78. Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address,
742 p.m.h.e. and C. Cross-Disorder Group of the Psychiatric Genomics, *Genomic*
743 *Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders*.
744 *Cell*, 2019. **179**(7): p. 1469-1482 e11.
- 745 79. Grotzinger, A.D., et al., *Genetic architecture of 11 major psychiatric disorders at*
746 *biobehavioral, functional genomic and molecular genetic levels of analysis*. *Nature*
747 *genetics*, 2022. **54**(5): p. 548-559.
- 748 80. Romero, C., et al., *Exploring the genetic overlap between twelve psychiatric disorders*.
749 *Nature genetics*, 2022: p. 1-8.
- 750 81. Pulit, S.L., et al., *Meta-analysis of genome-wide association studies for body fat*
751 *distribution in 694 649 individuals of European ancestry*. *Hum Mol Genet*, 2019. **28**(1): p.
752 166-174.
- 753 82. Maroofian, R., et al., *Biallelic variants in ADARB1, encoding a dsRNA-specific adenosine*
754 *deaminase, cause a severe developmental and epileptic encephalopathy*. *J Med Genet*,
755 2021. **58**(7): p. 495-504.
- 756 83. Kubota-Sakashita, M., et al., *A role of ADAR2 and RNA editing of glutamate receptors in*
757 *mood disorders and schizophrenia*. *Molecular brain*, 2014. **7**(1): p. 1-14.
- 758 84. Karanovic, J., et al., *Joint effect of ADARB1 gene, HTR2C gene and stressful life events on*
759 *suicide attempt risk in patients with major psychiatric disorders*. *World J Biol Psychiatry*,
760 2015. **16**(4): p. 261-71.
- 761 85. Clarke, T.K., et al., *Genome-wide association study of alcohol consumption and genetic*
762 *overlap with other health-related traits in UK Biobank (N=112 117)*. *Mol Psychiatry*, 2017.
763 **22**(10): p. 1376-1384.
- 764 86. Mahajan, A., et al., *Fine-mapping type 2 diabetes loci to single-variant resolution using*
765 *high-density imputation and islet-specific epigenome maps*. *Nat Genet*, 2018. **50**(11): p.
766 1505-1513.

- 767 87. Anstee, Q.M., et al., *Genome-wide association study of non-alcoholic fatty liver and*
768 *steatohepatitis in a histologically characterised cohort*(☆). *J Hepatol*, 2020. **73**(3): p.
769 505-515.
- 770 88. Santoro, N., et al., *Variant in the glucokinase regulatory protein (GCKR) gene is*
771 *associated with fatty liver in obese children and adolescents*. *Hepatology*, 2012. **55**(3): p.
772 781-789.
- 773 89. Willer, C.J., et al., *Discovery and refinement of loci associated with lipid levels*. *Nat Genet*,
774 2013. **45**(11): p. 1274-1283.
- 775 90. Barbon, A. and C. Magri, *RNA Editing and Modifications in Mood Disorders*. *Genes*
776 (Basel), 2020. **11**(8).
- 777 91. Albert, P.R., C. Benkelfat, and L. Descarries, *The neurobiology of depression—revisiting*
778 *the serotonin hypothesis. I. Cellular and molecular mechanisms*. 2012, The Royal Society.
779 p. 2378-2381.
- 780 92. Singh, M., et al., *Hyperphagia-mediated obesity in transgenic mice misexpressing the*
781 *RNA-editing enzyme ADAR2*. *Journal of Biological Chemistry*, 2007. **282**(31): p. 22448-
782 22459.
- 783 93. Horsch, M., et al., *Requirement of the RNA-editing enzyme ADAR2 for normal physiology*
784 *in mice*. *J Biol Chem*, 2011. **286**(21): p. 18614-22.
- 785 94. Levant, B., *N-3 (omega-3) polyunsaturated Fatty acids in the pathophysiology and*
786 *treatment of depression: pre-clinical evidence*. *CNS Neurol Disord Drug Targets*, 2013.
787 **12**(4): p. 450-9.
- 788 95. Gopaldas, M., et al., *Brain serotonin transporter binding, plasma arachidonic acid and*
789 *depression severity: A positron emission tomography study of major depression*. *J Affect*
790 *Disord*, 2019. **257**: p. 495-503.
- 791 96. Burghardt, K.J., et al., *Fatty Acid desaturase gene polymorphisms and metabolic*
792 *measures in schizophrenia and bipolar patients taking antipsychotics*. *Cardiovasc*
793 *Psychiatry Neurol*, 2013. **2013**: p. 596945.
- 794 97. Koga, N., et al., *Altered polyunsaturated fatty acid levels in relation to proinflammatory*
795 *cytokines, fatty acid desaturase genotype, and diet in bipolar disorder*. *Transl Psychiatry*,
796 2019. **9**(1): p. 208.
- 797 98. Brouwers, M., et al., *Modulation of Glucokinase Regulatory Protein: A Double-Edged*
798 *Sword?* *Trends Mol Med*, 2015. **21**(10): p. 583-594.
- 799 99. Tan, H.L., et al., *Association of glucokinase regulatory gene polymorphisms with risk and*
800 *severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene*. *J*
801 *Gastroenterol*, 2014. **49**(6): p. 1056-64.
- 802 100. Makela, T.N.K., et al., *Associations of serum n-3 and n-6 polyunsaturated fatty acids with*
803 *prevalence and incidence of nonalcoholic fatty liver disease*. *Am J Clin Nutr*, 2022. **116**(3):
804 p. 759-770.
- 805 101. Wootton, R.E., H.J. Jones, and H.M. Sallis, *Mendelian randomisation for psychiatry: how*
806 *does it work, and what can it tell us?* *Molecular psychiatry*, 2022. **27**(1): p. 53-57.
- 807 102. Bjornson, E., et al., *Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and*
808 *risk of coronary heart disease: a UK Biobank study*. *Eur Heart J*, 2023.

- 809 103. Brenna, J.T. and K.S.D. Kothapalli, *New understandings of the pathway of long-chain*
810 *polyunsaturated fatty acid biosynthesis*. *Curr Opin Clin Nutr Metab Care*, 2022. **25**(2): p.
811 60-66.
- 812 104. Mocking, R.J., et al., *Statistical methodological issues in handling of fatty acid data:*
813 *percentage or concentration, imputation and indices*. *Lipids*, 2012. **47**(5): p. 541-7.
- 814 105. Sergeant, S., et al., *Impact of methods used to express levels of circulating fatty acids on*
815 *the degree and direction of associations with blood lipids in humans*. *Br J Nutr*, 2016.
816 **115**(2): p. 251-61.
- 817 106. Brenna, J.T., et al., *Best practices for the design, laboratory analysis, and reporting of*
818 *trials involving fatty acids*. *Am J Clin Nutr*, 2018. **108**(2): p. 211-227.
- 819 107. Kothapalli, K.S., et al., *Positive Selection on a Regulatory Insertion-Deletion*
820 *Polymorphism in FADS2 Influences Apparent Endogenous Synthesis of Arachidonic Acid*.
821 *Mol Biol Evol*, 2016. **33**(7): p. 1726-39.
- 822 108. Ye, K., et al., *Dietary adaptation of FADS genes in Europe varied across time and*
823 *geography*. *Nat Ecol Evol*, 2017. **1**: p. 167.
- 824 109. Chiang, C.W.K., et al., *A Comprehensive Map of Genetic Variation in the World's Largest*
825 *Ethnic Group-Han Chinese*. *Mol Biol Evol*, 2018. **35**(11): p. 2736-2750.
- 826 110. Harris, K.M., M.J. Edlund, and S. Larson, *Racial and ethnic differences in the mental*
827 *health problems and use of mental health care*. *Med Care*, 2005. **43**(8): p. 775-84.
- 828 111. Breslau, J., et al., *Lifetime risk and persistence of psychiatric disorders across ethnic*
829 *groups in the United States*. *Psychol Med*, 2005. **35**(3): p. 317-27.
- 830


Triat1	Trait2	Genetic correlation		MR		Colocalization			A1	A2	β_1 (SE1)	β_2 (SE2)	P1	P2
		r_g	P	β_{IVW}	P_{IVW}	colocalized regions	PP	Candidate SNP						
Strong evidence														
PUFA%	MDD	-0.193	7.14E-16	-0.051	0.006	chr21q22.3	0.829	rs4818766	G	A	-0.019 (0.004)	0.022 (0.005)	1.30E-06	6.38E-07
PUFA%	AUDIT_C	0.116	2.0E-3	0.014	0.019	chr2p23.2	0.996	rs1260326	C	T	0.090 (0.004)	0.007 (0.001)	9.8E-113	5.47E-09
Omega-6%	AUDIT_C	0.084	0.036	0.019	0.001	chr2p23.2	0.996	rs1260326	C	T	0.109 (0.004)	0.007 (0.001)	7.0E-159	5.47E-09
PUFA%	AUDIT_T	0.079	0.037	0.014	0.049	chr2p23.2	0.999	rs1260326	C	T	0.090 (0.004)	0.008 (0.001)	9.8E-113	2.11E-10
Suggestive evidence														
LA%	ADHD	-0.338	3.25E-13	-0.070	0.230	chr9q21.32	0.768	rs2576362	T	G	0.025 (0.005)	-0.067 (0.015)	8.20E-08	1.30E-05
PUFA%	ADHD ^a	-0.301	2.51E-12	-0.089	0.151	chr9q21.32	0.722	rs6559744	A	G	0.025 (0.005)	-0.067 (0.015)	1.90E-08	1.26E-05
DHA%	AN	0.276	6.35E-12	0.072	0.248	chr6q16.1	0.797	rs1487445	T	C	0.020 (0.004)	0.056 (0.013)	4.30E-07	2.70E-05
Omega-6%	ADHD ^a	-0.254	5.67E-08	-0.062	0.306	chr9q21.32	0.755	rs1982151	G	A	-0.026 (0.005)	0.068 (0.015)	1.70E-08	1.04E-05
PUFA%	SCZ	0.100	2.0E-4	0.062	0.364	chr12q24.31	0.858	rs2851447	C	G	-0.022 (0.005)	-0.091 (0.012)	1.70E-06	2.19E-14
						chr1p36.11	0.854	rs79598313	T	C	-0.081 (0.013)	-0.141 (0.035)	3.00E-09	4.86E-05
Omega-3%	SCZ	0.091	0.006	0.013	0.815	chr6p21.33	0.818	rs2596500	C	A	-0.027 (0.006)	-0.166 (0.018)	1.10E-06	1.16E-19
Omega-6%	SCZ	0.077	0.006	0.015	0.779	chr12q24.31	0.702	rs2851447	C	G	-0.024 (0.005)	-0.091 (0.012)	2.30E-07	2.19E-14
Omega-6: Omega-3	BIP	-0.068	0.042	0.041	0.429	chr6p22.1	0.790	rs3094067	G	T	0.029 (0.006)	-0.103 (0.016)	7.20E-06	9.88E-11
						chr6p21.33	0.877	rs3130490	T	G	0.028 (0.006)	-0.082 (0.016)	3.30E-06	1.30E-07

1 Table 1. Evidence supporting the potential role of cPUFAs in brain disorders

2 Note: r_g , genetic correlation; β_{IVW} , estimated effects of trait 1 on trait 2 using IVW method; PP, posterior probability. A1, effect allele; A2, reference allele. β_1 , SE1 and β_2 , SE2 are
3 genetic effects and standard errors of A1 on trait 1 and trait 2, respectively. P1 and P2 are P values for trait 1 and trait 2 extracted from GWAS summary statistics, respectively.

4 ^aThe reverse MR of the two PUFA-ADHD pairs showed significant results ($P_{IVW} < 0.05$).

835 **Figures**



836

837 **Figure 1: Widespread, moderate genetic basis shared between cPUFAs and brain disorders.**

838 **A)** Pairwise genetic correlations between six cPUFAs and 20 brain disorders. P-value cutoffs of

839 0.05, 0.001, 4.17×10^{-4} are used to represent increasing levels of statistical significance; colors are

840 used to represent degree of genetic correlation (r_g) between two traits. **B)** Pairwise polygenic

841 overlaps between six cPUFAs and 15 brain disorders. The color and number of each box indicate

842 the degree of polygenic overlap and number of causally associated SNPs shared between

843 cPUFAs and brain disorders (nc_{12}). Bar plots on the top and left indicate the number of cPUFAs-


844 and brain disorders- associated variants, respectively, which explain 90% of SNP-based

845 heritability. Two cPUFA-brain disorder pairs highlighted in the red boxes correspond to panels C)


846 and D). **C)** Genetic effects of genome-wide SNPs on PUFA% (x axis) and NE (y axis). **D)**

847 Genetic effects of genome-wide SNPs on LA% (x axis) and AUDIT_C (y axis). Each dot

848 represents a genetic variant; colors indicate variant density.




849
 850 **Figure 2. Statistical inference of causal relationship between cPUFAs and brain disorders.**
 851 **A)** A heatmap summarizing the effects of six cPUFAs on 17 brain disorders. IVW p-value of 0.05
 852 is used to represent statistical significance. Colors represent the effects (β_{IVW}) of cPUFAs on
 853 brain disorders. The pair of omega-3% and BIP highlighted in the red box corresponds to panel
 854 **C).** **B)** MR results showing a significant association between cPUFAs and brain disorders. Beta
 855 and OR estimated using IVW method are used to represent the effects of cPUFAs on continuous
 856 and binary outcomes, respectively. **C)** MR estimated effects of omega-3% (x axis) on BIP (y
 857 axis). Effects estimated by the four models are shown by fitted lines; slopes of these lines
 858 indicate the effect sizes.



859
 860 **Figure 3. Colocalization analysis detects genomic loci shared between cPUFAs and brain**
 861 **disorders.** **A)** A heatmap summarizing pairwise colocalization between six cPUFAs and 17 brain
 862 disorders. The color and number of each box indicate the number of significant colocalized
 863 regions between cPUFAs and brain disorders ($PP > 0.7$). Bar plots on the top and left indicate the
 864 numbers of unique colocalized SNPs (black) and loci (grey, $PP > 0.7$) for cPUFAs and brain
 865 disorders, respectively. **B)** Regional association plots of six cPUFA phenotypes and BIP in
 866 chr11:61,520,000-61,660,000. Variant positions are shown on x axis, $-\log_{10}P$ on the left y axis,
 867 recombination rate on the right y axis; variant rs174564 is marked as the lead SNP; genes located
 868 in the region are shown in the bottom. LD r^2 values are indicated by colors, and recombination

869 rates by curves. C) Multi-trait colocalization analysis combining six cPUFA phenotypes and BIP
 870 identified a putative shared causal variant rs174564 (PP = 0.95). PP values are shown on y axis.



871 **Figure 4. Evidence supporting the effect of omega-6% on alcohol consumption.** A) Genetic
 872 effects of genome-wide SNPs on omega-6% (x axis) and AUDIT_C (y axis). Each dot represents
 873 a genetic variant; colors indicate the variant density. B) MR estimated effects of omega-6% (x
 874 axis) on AUDIT_C (y axis). Effects estimated by the four models are shown by fitted lines;
 875

876 slopes of these lines indicate the effect sizes. **C)** Regional association plots of five cPUFA
877 phenotypes and three alcohol consumption phenotypes in chr2:276,000,000-27,900,000. Variant
878 positions are shown on x axis, $-\log_{10}P$ on the left y axis, recombination rate on the right y axis;
879 variant rs1260326 is marked as the lead SNP; genes located in the region are shown in the
880 bottom. LD r^2 values are indicated by colors, and recombination rates by curves. **D)** Multi-trait
881 colocalization analysis combining five cPUFA phenotypes and three alcohol consumption
882 phenotypes identified a shared putative causal variant rs1260326 (PP = 0.99). PP values are
883 shown on y axis.